SA
BSX icon

Strategic Advocates’s Boston Scientific BSX Stock Holding History

Strategic Advocates’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.1K Sell
751
-1,322
-64% -$71.8K 0.12% 106
2026
Q1 		$130K Sell
2,073
-25,392
-92% -$2.03M 0.58% 40
2025
Q4 		$2.64M Buy
27,465
+3,358
+14% +$329K 0.67% 24
2025
Q3 		$2.35M Buy
24,107
+2,697
+13% +$279K 0.61% 28
2025
Q2 		$2.3M Buy
21,410
+1,517
+8% +$153K 0.68% 26
2025
Q1 		$2.01M Buy
+19,893
New +$2M 0.7% 26

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Strategic Advocates's BSX Position: Q2 2026 in Review

Strategic Advocates reduced its Boston Scientific (BSX) stake by 64% in Q2 2026, selling an estimated $71.8K and leaving 751 shares worth $32.1K. The position accounts for 0.12% of the portfolio, ranked #106.

Strategic Advocates first reported a position in BSX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.64M in Q4 2025. 1,477 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Strategic Advocates held 751 shares of Boston Scientific worth $32.1K as of Q2 2026.
  • Strategic Advocates sold 1,322 Boston Scientific shares in Q2 2026, an estimated $71.8K.
  • Boston Scientific made up 0.12% of Strategic Advocates's portfolio in Q2 2026, its #106 holding.
  • Strategic Advocates first reported a position in Boston Scientific in Q1 2025 and has held it in 6 quarters since.
  • Strategic Advocates's Boston Scientific position peaked at $2.64M in Q4 2025.
  • 1,477 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.